Automated Insulin Delivery Systems Show Long-Term Benefits for Young People With Type 1 Diabetes

Researchers used a modeling approach to compare the long-term costs and health outcomes of automated insulin delivery systems versus traditional multiple daily injections combined with continuous glucose monitoring. The analysis included real-world data from 251 children and adolescents in England who participated in a national AID pilot program. They tracked potential outcomes over 55 years—essentially from childhood through adulthood—across Australia, Canada, the UK, and the USA.

Young people using AID systems showed better blood sugar control in the first year, with an average HbA1c reduction of 0.63%. The study projected that over a 55-year period, AID systems would result in quality-of-life gains ranging from 1.35 to 2.72 quality-adjusted life years (QALYs), a standard measure of health benefit that combines length and quality of life.

One of the most significant findings was the reduced risk of long-term Type 1 diabetes complications. The analysis projected that using AID systems would reduce the risk of proliferative diabetic retinopathy (advanced eye disease) by 51.3%, end-stage renal disease by 39.5%, and severe vision loss by 38.8%. These reductions reflect how better blood sugar control over many years can protect organs most vulnerable to diabetes-related damage.

When researchers calculated the long-term costs and benefits, AID systems proved cost-effective or cost-saving across all four countries studied. Australia saw the highest total cost savings at USD 9,340, while Canada showed the greatest savings at USD 28,798. The cost-effectiveness ratios—a measure of cost per health benefit gained—ranged from USD 14,590 per QALY in Australia to USD 35,648 per QALY in the USA. These findings suggest that the upfront investment in AID technology pays off through prevented complications and reduced long-term health care costs.

This study adds to evidence that automated insulin delivery systems are valuable tools for managing Type 1 diabetes in children and adolescents. By improving daily blood sugar control and reducing the risk of serious complications over time, AID systems can help young people live healthier, longer lives. The economic analysis shows that these benefits extend beyond individual health—they represent sound investments from a health care system perspective as well.

Source: Diabetes technology & therapeutics. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.